作者
Ramesh K Ramanathan, Chandra P Belani, Deepti A Singh, Michael Tanaka, Heinz-Josef Lenz, Yun Yen, Hedy L Kindler, Syma Iqbal, Jeff Longmate, Philip C Mack, Georg Lurje, Regina Gandour-Edwards, Janet Dancey, David R Gandara
发表日期
2009/9
期刊
Cancer chemotherapy and pharmacology
卷号
64
页码范围
777-783
出版商
Springer-Verlag
简介
Purpose
To evaluate the response to lapatinib, an inhibitor of epidermal growth factor receptors 1 and 2, in patients with advanced bilary tree cancer (BTC) and hepatocellular cancer (HCC).
Methods
Lapatinib was dosed at 1,500 mg/day orally continuously.
Results
Fifty-seven patients were accrued (BTC 17, HCC 40). Therapy was well tolerated. The response in BTC was 0% and in HCC was 5%. The progression free survival (PFS) for BTC and HCC patients was 1.8 (95% CI: 1.7–5.2) months and 2.3 (95% CI: 1.7–5.6) months. The median survival for BTC and HCC patients was 5.2 (95% CI 3.3–∞) months and 6.2 (95% CI: 5.1–∞) months. EGFR genotyping indicated HCC patients with <20 repeats have the lowest PFS. The occurrence of any skin rash significantly prolonged PFS and survival …
引用总数
学术搜索中的文章
RK Ramanathan, CP Belani, DA Singh, M Tanaka… - Cancer chemotherapy and pharmacology, 2009